BALTIMORE, MD--(Marketwired - Apr 19, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has issued a research report which provides an updated valuation of Nuvilex Inc. (
Nuvilex is primarily known for its proprietary, multi-functional, biomedical therapeutic enhancement platform which has been used in clinical trials, notably a Phase 2 pancreatic cancer trial that generated very favorable results. This platform, which essentially serves as an existing therapy booster, is based upon its live-cell encapsulation technology and delivery system and enhances the quality of life.
In the Goldman Opportunity Research report on the Company, analyst Rob Goldman outlines his investment thesis.
"Following exhaustive due diligence of anti-cancer biotechs and biopharmaceuticals, we believe that the Street is significantly undervaluing Nuvilex's shares. Given the strong Phase 2 pancreatic cancer trial results, and based on traditional valuations for firms at this stage, we believe that NVLX could be afforded a much higher valuation just for its live-cell encapsulation therapy for use in pancreatic cancer alone. According to our survey, a valuation of $70M is generally in line with the typical valuations afforded a number of oncology companies at this stage of development."
To view a summary of the report or download the report in its entirety, please visit
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (